Method for treating arteriosclerosis
    1.
    发明授权
    Method for treating arteriosclerosis 有权
    治疗动脉硬化的方法

    公开(公告)号:US07419955B2

    公开(公告)日:2008-09-02

    申请号:US10514715

    申请日:2003-05-26

    IPC分类号: A61K38/00

    CPC分类号: A61K38/2264 A61K48/00

    摘要: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

    摘要翻译: 清道夫受体A表达下调和用于预防或治疗动脉硬化的药物,其含有脂联素,脂联素或编码结构域或脂联素的基因的C-末端球状结构域作为活性成分。 根据本发明,提供能够直接防止内膜增厚的预防或治疗剂,其构成动脉硬化的基本特征。 通过降低动脉壁中清道夫受体A的表达水平并防止巨噬细胞中的脂质积聚,可以通过阻止动脉硬化的发生和发展来实现该效果。

    Preventive/remedy for arteriosclerosis
    2.
    发明申请
    Preventive/remedy for arteriosclerosis 有权
    动脉硬化的预防/治疗

    公开(公告)号:US20060166873A1

    公开(公告)日:2006-07-27

    申请号:US10514715

    申请日:2003-05-26

    IPC分类号: A61K48/00 A61K38/17

    CPC分类号: A61K38/2264 A61K48/00

    摘要: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

    摘要翻译: 清道夫受体A表达下调和用于预防或治疗动脉硬化的药物,其含有脂联素,脂联素或编码结构域或脂联素的基因的C-末端球状结构域作为活性成分。 根据本发明,提供能够直接防止内膜增厚的预防或治疗剂,其构成动脉硬化的基本特征。 通过降低动脉壁中清道夫受体A的表达水平并防止巨噬细胞中的脂质积聚,可以通过阻止动脉硬化的发生和发展来实现该效果。

    Substance preventing adverse actions of therapeutic agents for dyslipidemia
    5.
    发明申请
    Substance preventing adverse actions of therapeutic agents for dyslipidemia 审中-公开
    防止治疗剂对血脂异常的不良反应的物质

    公开(公告)号:US20100098720A1

    公开(公告)日:2010-04-22

    申请号:US12385961

    申请日:2009-04-24

    IPC分类号: A61K36/02

    摘要: A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from Dunaliella salina or Dunaliella bardawil, for administration in combination with the fibrate-series drugs. The substance suppresses liver hypertrophy caused by the fibrate-series drugs as PPAR-α agonists and has an action of promoting fat combustion, suppressing fat synthesis and suppressing cell proliferation, to prevent disorders of liver functions.

    摘要翻译: 防止常规贝特类药物作为代谢综合征和血脂异常的治疗剂以增强其治疗效果的不良作用的物质包括与盐酸杜氏盐藻(Dunaliella salina)或杜氏盐藻(Dunaliella bardawil)一起提取物,用于与贝特类药物组合施用。 该物质抑制作为PPAR-α激动剂的贝特类药物引起的肝肥大,并具有促进脂肪燃烧,抑制脂肪合成和抑制细胞增殖的作用,以防止肝功能障碍。

    Adiponectin receptor and gene encoding the same
    6.
    发明申请
    Adiponectin receptor and gene encoding the same 有权
    脂联素受体和基因编码相同

    公开(公告)号:US20100062541A1

    公开(公告)日:2010-03-11

    申请号:US12322111

    申请日:2009-01-29

    IPC分类号: C07K14/435 G01N33/566

    CPC分类号: C07K14/72 Y10S435/81

    摘要: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.

    摘要翻译: 目的是分离和鉴定人和小鼠脂联素受体,以提供具有脂联素结合能力的新型蛋白质,并提供使用这种蛋白质的脂联素受体的配体,激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的,使用蛋白质作为具有脂联素结合能力的新型蛋白质,即(a)包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8,或(b)包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失,替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。

    Adiponectin expression-inducing agents and uses thereof
    7.
    发明申请
    Adiponectin expression-inducing agents and uses thereof 失效
    脂联素表达诱导剂及其用途

    公开(公告)号:US20070203061A1

    公开(公告)日:2007-08-30

    申请号:US10594969

    申请日:2005-03-31

    摘要: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.

    摘要翻译: 本发明提供了脂联素表达诱导剂和使用其的治疗剂用于肥胖症和肥胖相关疾病如心血管疾病或代谢疾病,以及搜索脂联素表达诱导剂的方法。 KLF9可以结合位点-188的32-bp片段,从脂联素表达起始位点到位置-157,证明增强脂连蛋白启动子活性。 因此,本发明使用KLF9作为脂联素表达诱导剂,并且表明KLF9补充疗法可用于预防和/或治疗肥胖症或肥胖相关疾病,包括诸如胰岛素抵抗和II型糖尿病等代谢疾病和心血管疾病 。

    Adiponectin receptor and gene encoding the same
    9.
    发明授权
    Adiponectin receptor and gene encoding the same 有权
    脂联素受体和基因编码相同

    公开(公告)号:US08252584B2

    公开(公告)日:2012-08-28

    申请号:US13153017

    申请日:2011-06-03

    CPC分类号: C07K14/72 Y10S435/81

    摘要: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.

    摘要翻译: 目的是分离和鉴定人和小鼠脂联素受体,以提供具有脂联素结合能力的新型蛋白质,并提供使用这种蛋白质的脂联素受体的配体,激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的,使用蛋白质作为具有脂联素结合能力的新型蛋白质,即(a)包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8,或(b)包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失,替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。

    Adiponectin receptor and gene encoding the same
    10.
    发明授权
    Adiponectin receptor and gene encoding the same 有权
    脂联素受体和基因编码相同

    公开(公告)号:US07977459B2

    公开(公告)日:2011-07-12

    申请号:US12322111

    申请日:2009-01-29

    IPC分类号: C07K1/00 G01N33/53 G01N33/566

    CPC分类号: C07K14/72 Y10S435/81

    摘要: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.

    摘要翻译: 目的是分离和鉴定人和小鼠脂联素受体,以提供具有脂联素结合能力的新型蛋白质,并提供使用这种蛋白质的脂联素受体的配体,激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的,使用蛋白质作为具有脂联素结合能力的新型蛋白质,即(a)包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8,或(b)包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失,替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。